Linked Life Data

6717272

Source:http://linkedlifedata.com/resource/pubmed/id/6717272

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1984-6-5
pubmed:abstractText
The pheochromocytoma-scanning agent 131I-meta-iodobenzylguanadine (131I-MIBG) was concentrated in the platelets of ten subjects undergoing scans for suspected pheochromocytomas. In vitro studies also demonstrated that 131I-MIBG was concentrated in platelets. In contrast to serotonin, which had maximum in vitro platelet uptake of one hour, the peak in vitro platelet uptake of 131I-MIBG did not occur until six hours. In vitro platelet 131I-MIBG uptake was decreased by 79% to 98% following the neuronal-uptake-blocking agent imipramine. These studies suggest that pheochromocytomas take up 131I-MIBG by a neuronal-pump mechanism. Further studies to determine if 131I-MIBG is taken up by other tumors with a neuronal-pump mechanism, such as carcinoid tumors, will be valuable.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0026-0495
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
397-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Platelet uptake of the pheochromocytoma-scanning agent 131I-meta-iodobenzylguanadine.
pubmed:publicationType
Journal Article, Comparative Study, In Vitro, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't